Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab: A Case Report.

Abstract

PURPOSE:

To report a case of multiple sclerosis (MS) development in a patient with Juvenile Idiopathic Arthritis (JIA) and bilateral intermediate uveitis (IU) treated with Adalimumab.

CASE REPORT:

A 21-year-old Colombian woman diagnosed with JIA and bilateral refractory IU treated with methotrexate and Adalimumab with difficult control of the disease and multiple ocular complications. Eight years after starting Adalimumab, the patient presented paresthesia in the left upper limb. Radiologic findings in the brain and cervical spine MRI confirmed the diagnosis of MS.

CONCLUSIONS:

We reported the first case of MS development in a patient with JIA treated with Adalimumab and the third in a patient with noninfectious uveitis treated with anti-TNFα. It remains uncertain whether MS is secondary to anti-TNFα therapy or is linked to a polyautoimmunity phenomenon.

• Authors: William Rojas-Carabali, Laura Boada-Robayo, Daniela Chacón-Zambrano, Eveling Criollo Porras, Valentina Kerguelén Dumar, Alejandra de-la-Torre
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) Vol. 31 Issue 9 Pg. 1873-1876 (Nov 2023) ISSN: 1744-5078 [Electronic] England
• PMID: 36150118 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adalimumab
• Antirheumatic Agents

Topics

• Female
• Humans
• Young Adult
• Adult
• Adalimumab (adverse effects)
• Arthritis, Juvenile (complications, diagnosis, drug therapy)
• Antirheumatic Agents (adverse effects)
• Multiple Sclerosis (drug therapy)
• Uveitis (diagnosis, drug therapy, etiology)
• Uveitis, Intermediate (complications, diagnosis, drug therapy)